<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527718</url>
  </required_header>
  <id_info>
    <org_study_id>SSGJ-611-HV-I-A</org_study_id>
    <nct_id>NCT04527718</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double Blinded, Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of 611 in Adult Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation&#xD;
      study to evaluate the safety, tolerability, and PK of 611 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study period per subject is about 4 months broken down as follows:&#xD;
&#xD;
      The screening period is up to 28 days, one dose treatment, and follow- up period is up to 90&#xD;
      +/- 9 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With TEAEs</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs) will be summarized by SOC and PT for each treatment group, and also be summarized by severity and association with the study treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK</measure>
    <time_frame>up to 90 days</time_frame>
    <description>PK parameters not limit to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immunogenicity</measure>
    <time_frame>up to 90 days</time_frame>
    <description>ADA, and NAbs if ADA is positive</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>611 dose 1 (45mg) plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>611 dose 2 (150mg) plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>611 dose 3 (300mg) plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>611 dose 4 (450mg) plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>611 dose 5 (600mg) plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo as a single SC injection on Day 1;</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>611</intervention_name>
    <description>611 as a single SC injection on Day 1;</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and willing to sign the ICF&#xD;
&#xD;
          2. Healthy male and female subjects, non-smokers, 18-55 years of age&#xD;
&#xD;
          3. In the opinion of the investigator, with no significant medical history, and in good&#xD;
             health.&#xD;
&#xD;
          4. Body mass index 19.0-32.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for&#xD;
             females.&#xD;
&#xD;
          5. Subjects are able to follow the study protocol and complete the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to similar drugs to 611 or their excipients.&#xD;
&#xD;
          2. Pregnant, or nursing females.&#xD;
&#xD;
          3. HepBsAg or HepCAb positive.&#xD;
&#xD;
          4. Human immunodeficiency virus (HIV) positive.&#xD;
&#xD;
          5. Positive urine drug screen, or cotinine test.&#xD;
&#xD;
          6. Any reason which, in the opinion of the Qualified Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeanelle Kam, MD</last_name>
    <phone>214-647-9300</phone>
    <email>Jeanelle.Kam@covance.com</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

